KaloBios Pharma (NASDAQ: KBIO) new CEO Martin Shkreli just tweeted a picture of himself and others at the company's headquarters captioned "turnaround in progress."

Shares have surged from $0.90 to over $45 in a few days amid news a Shkreli group has accumulated nearly the entire float and will takeover as CEO, staving off a wind-down. An epic short squeeze has ensued.

Turnaround in progress. $KBIO pic.twitter.com/5dseMG3B8I

— Martin Shkreli (@MartinShkreli) November 23, 2015

Management Comments Momentum Movers Short Sales Trader Talk

KaloBios Pharma (KBIO) Could Drop 50% By Early Next Week: Tim SykesNovember 24, 2015 12:46 PM KaloBios Pharma (KBIO) Receives NASDAQ Delisting NoticeNovember 23, 2015 5:46 PM Cleveland Biolabs (CBLI) Sees Mid-Day Upside on KBIO ComparisonNovember 23, 2015 12:36 PM KaloBios Pharma (KBIO) Halted Again on LUDPNovember 23, 2015 12:18 PM KaloBios Pharma (KBIO) triggers limit-up, limit-down trading pauseNovember 23, 2015 12:01 PM KaloBios Pharmaceuticals (KBIO) Squeezes Toward $30/ShareNovember 23, 2015 11:17 AM